Brukinsa

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
Flag link:
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Fierce Pharma
BeiGene
Brukinsa
earnings
tislelizumab
Flag link:
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
BeiGene
Brukinsa
CLL
FDA
Imbruvica
Flag link:
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
ASH 2022
Eli Lilly
BeiGene
Nurix Therapeutics
Brukinsa
pirtobrutinib
NX-2127
Flag link:
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
BeiGene
AbbVie
JNJ
Imbruvica
blood cancers
Brukinsa
Flag link:
ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa fleshes out competitive leukemia data again
Fierce Biotech
BeiGene
Brukinsa
leukemia
clinical trials
AbbVie
JNJ
Imbruvica
Flag link:
FDA grants BeiGene's Brukinsa accelerated approval in marginal zone lymphoma
FDA grants BeiGene's Brukinsa accelerated approval in marginal zone lymphoma
Seeking Alpha
BeiGene
Brukinsa
FDA
accelerated approvals
marginal zone lymphoma
Flag link:
FDA approves BeiGene's Brukinsa in rare blood cancer amid company's US expansion plans
FDA approves BeiGene's Brukinsa in rare blood cancer amid company's US expansion plans
Endpoints
BeiGene
Brukinsa
blood cancer
FDA
Flag link:
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
BeiGene tees up 3-way leukemia competition against J&J-AbbVie, AstraZeneca with Brukinsa win
Fierce Pharma
BeiGene
Brukinsa
CLL
small lymphocytic lymphoma
clinical trials
Flag link:
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Flag link:
Important catalysts approach for smaller biotechs
Important catalysts approach for smaller biotechs
EP Vantage
BeiGene
Turning Point Therapeutics
Intra-Cellular Therapies
Immunovant
Caplyta
Brukinsa
repotrectinib
IMVT-1401
clinical trials
Flag link:
3 Blockbuster Cancer Drug Launches to Watch in 2020
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Flag link:
5 New Drug Approvals the FDA Gave Top Priority
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:
China's BeiGene gets FDA approval for drug to treat rare form of lymphoma
China's BeiGene gets FDA approval for drug to treat rare form of lymphoma
Yahoo/Reuters
BeiGene
China
FDA
Brukinsa
mantle cell lymphoma
Flag link: